H Clinical supports all therapeutic areas. Whether a small rare disease trial or a large-scale vaccine study, we have the home visit services and infrastructure to meet your needs and that will make a difference to your patients and the trial outcome.

Trials in all therapeutic areas benefit from home visits.

They expand recruitment for hard to find patients in challenging indications, they improve retention for studies requiring long term follow-up, and they support patient engagement by reducing travel and the stress many feel when at a medical clinic.

We understand the challenges and opportunities of drug development in each therapeutic area and the importance of bringing new products to market that will positively impact human health. Our skilled home health providers are there to support your trial, your life changing product, and to deliver quality interactions with research participants across all diseases and conditions.


In-home visit, project management, depot, and logistics services for your therapeutic area.

Cardiovascular – Home visits make research more accessible to older populations, improve and expand recruitment, and help assess patients in a more real world setting.

Dermatology – Home visits shift and expand the recruitment paradigm for dermatology indications that must contend with significant competition for participants and site resources.

Gastroenterology – Home visits help sponsors access patients in Latin America where diseases like NASH are prevalent. They also improve patient engagement and retention.

Immunology and Rheumatology – Home visits help those with chronic pain or mobility restrictions.

Infectious Diseases – Home visits provide an expanded scope in which to recruit by facilitating research in more rural areas where infectious disease is common. These visits also reduce the risk of the disease spreading by not requiring travel to the research clinic.

Metabolic and Endocrine – These trials are often long term studies at risk for patient dropout. Home visits reduce the burden on the research participant and keep the participant engaged.

Neuroscience – Home visits enable a continuum of participant follow up as cognition or mobility changes and they lessen the impact of trial participation on patient caregivers.

Oncology and Hematology – Home visits support immunocompromised patients.

Ophthalmology – Home visits improve enrollment and reduce or eliminate travel that is challenging for individuals with conditions that impact sight.

Pediatrics – Home visits allow children to remain in the comfort of their home and help parents with rigid work schedules, who have limited time off, or who cannot afford to miss work.

Rare Diseases – Hybrid or decentralized trial models with home visits benefit rare disease trials with dispersed populations and hard to find patients.

Respiratory – Respiratory conditions like COPD, Cystic Fibrosis, and Asthma place patients at higher risk for severe illness if they contract COVID-19. Home visits reduce the risk of exposure and decrease patient stress.

Urology – Home visits decrease the discomfort of travel and help ease the perceived embarrassment sometimes associated with urological diseases or conditions.

Vaccines – Home visits support fast and high enrolling trials at sites that would otherwise not have the staffing or space capacity to perform follow up visits.

Women’s Health – Innovative trial models and home visits improve the recruitment of a patient population historically difficult to enroll and home visits permit women to stay in the comfort of home during pregnancy, if desired.